Jason Roth, DO
Pain Medicine · Wilmington, DENPI 1134514706
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,543 and has fallen 89.4% since, to $164 in 2025.
Across 186 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$833
- Scilex Pharmaceuticals Inc.$755
- Collegium Pharmaceutical, Inc.$506
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$361
- Vertos Medical, Inc.$275
- Biohaven Pharmaceutical Holding Company Ltd.$208
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,439100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 17 | $833 |
| Scilex Pharmaceuticals Inc. | 30 | $755 |
| Collegium Pharmaceutical, Inc. | 33 | $506 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $361 |
| Vertos Medical, Inc. | 5 | $275 |
| Biohaven Pharmaceutical Holding Company Ltd. | 15 | $208 |
| Boston Scientific | 6 | $173 |
| Valinor Pharma, LLC | 8 | $173 |
| Abbott | 9 | $155 |
| Menarini Silicon Biosystems, Inc. | 3 | $145 |
| SPR Therapeutics, Inc | 1 | $110 |
| Relievant Medsystems, Inc. | 1 | $102 |
| Pfizer | 6 | $92 |
| Biohaven Pharmaceuticals, Inc. | 5 | $78 |
| Novo Nordisk | 4 | $75 |
| IBSA Pharma Inc. | 3 | $73 |
| Redhill Biopharma Inc. | 4 | $71 |
| Biotronik NRO, Inc. | 1 | $52 |
| Biodelivery Sciences International, Inc. | 3 | $42 |
| Tersera Therapeutics LLC | 2 | $38 |
| Acella Pharmaceuticals, LLC | 2 | $34 |
| Nevro Corp. | 1 | $25 |
| Teleflex LLC | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Forte Bio-pharma LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS$265
- INTELLIS ADAPTIVESTIM$253
- Intracept$204
- ZTLido$146
- mild Device Kit$121
- CELLSEARCH$110
- SPRINT PNS System$110
How this compares
$4,439 in reported general payments places this provider in the 60th percentile of 31 pain medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MovantikNaloxegol Oxalate | 73 | $30,768 |
| Xtampza ErOxycodone Myristate | 33 | $26,909 |
| BelbucaBuprenorphine Hcl | 27 | $21,657 |
| ZtlidoLidocaine | 18 | $15,865 |
| OxycontinOxycodone Hcl | 21 | $12,570 |
| Lidocaine | 66 | $6,729 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 189 | $6,110 |
| Tizanidine Hcl | 219 | $5,620 |
| Oxycodone Hcl | 184 | $3,645 |
| Buprenorphine | 11 | $3,274 |
| Tramadol Hcl ErTramadol Hcl | 45 | $2,326 |
| Gabapentin | 163 | $1,856 |
| Pregabalin | 122 | $1,761 |
| Fentanyl | 14 | $1,496 |
| Morphine Sulfate ErMorphine Sulfate | 57 | $1,446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $506 | $48,56660 claims |
| Redhill Biopharma Inc.Movantik | $71 | $30,76873 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $755 | $15,86518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 31 pain medicine providers in Delaware.
Other pain medicine in Wilmington
- Selina XingWilmington$13K
- Alexander MatzWilmington$6K
- Daniel NasrWilmington$6K
- Sriniketh SundarWilmington$5K
- Amir Abdel KaderWilmington$5K
- Chiedozie UwanduWilmington$4K
- Manny LaiWilmington$4K
- Chee WooWilmington$3K
- Yasmin ElkhashabWilmington$2K
- Peter WitherellWilmington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.